Setting a one-year window for subsequent funding is an oversimplification; liquidity is too rare for that.
Actual funding cycles depend on many factors; time is a finite and valuable resource that cannot be standardized.
A year might be a luxury for some startups, while others, like those in biotech, require much longer to reach their milestones.
This single window does not account for the variable lifespan of resources available to these companies.
For example, a Swiss startup focused on deeptech might need 2 to 3 years to demonstrate the viability of its technology before attracting a second significant round, making the one-year limit totally unrealistic.